Skip to main content
Premium Trial:

Request an Annual Quote

Optibrium, Molecular Networks to Share Tech Platforms

NEW YORK (GenomeWeb News) – Optibrium and Molecular Networks today said that they will share complementary technology platforms for the drug discovery market.

The collaboration will integrate Molecular Networks' 3D structure generator, Corina, into Optibrium's StarDrop, a platform for guiding compound selection and design.

According to the firms, Corina is used within StarDrop's predictive P450 metabolism models, which identify metabolic liabilities of candidate molecules against the major cytochrome P450 enzymes.

"The seamless integration of CORINA within StarDrop has enabled our P450 metabolism models to provide more reliable data in support of the drug design and optimisation process," Matthew Segall, CEO of Cambridge, UK-based Optibrium, said in a statement. "We are looking forward to providing access to more of Molecular Network's chemoinformatics tools through StarDrop to further benefit our customers."

Financial and further terms of the alliance were not disclosed.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.